New immunotherapy combo aims to improve lung cancer outcomes

NCT ID NCT07619911

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests an immunotherapy drug called SHR-1701 combined with chemotherapy and radiation for people with unresectable stage III non-small cell lung cancer. The study will enroll 84 participants and compare giving SHR-1701 before or after standard chemoradiation. The main goal is to see if the drug can delay cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1701 (an immunotherapy drug) combined with platinum-based chemotherapy and radiation
What this could lead to: If successful, this could help determine the best timing for adding immunotherapy to standard chemoradiation for stage III lung cancer, potentially improving how long patients live without their cancer growing.
What could go wrong: This is an early phase II trial with only 84 people, so results are preliminary. Immunotherapy can cause immune-related side effects, and the drug may not work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMORADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIOTHERAPY NSCLC, STAGE III SHR-1701

More trials for these conditions

Other studies related to the condition(s) this trial covers.